UCB Stem Cells for Autism Spectrum Disorders

PHASE1CompletedINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

November 4, 2019

Primary Completion Date

January 31, 2021

Study Completion Date

July 31, 2021

Conditions
Autism Spectrum Disorder
Interventions
OTHER

umbilical cord blood mononuclear stem cells

UCB samples (70-130 ml of initial volume) were aseptically drained in blood-collection bags with 35 mL of citrate phosphate dextrose (CPDA-1) anticoagulant. Red blood cell-depleted/plasma-reduced nucleated cells were isolated by sedimentation in dextran-40, resuspended in autologous plasma with 10% dimethylsulfoxide and 1% dextran-40, and aliquoted in 3.8 ml vials with target doses of 3.0±0.2 x 10⁶ cells per vial. Vials were cooled to -90⁰C, quarantined in the vapor phase of liquid nitrogen. Tested for HIV-1/2, hepatitis B and C, HTLV-1/2, HSV-1 and -2, CMV, syphilis, and sterility. Characterized by AB0/Rh, CD34/CD45-positive cell content. Before injection sample thaws in the water bath at +37⁰C and washes from an excess amount of DMSO in 40 mL of physiological saline containing 2.5% human serum albumin and 5% dextran-40. After centrifugation and supernatant withdrawal, the UCB resuspends in 40 ml of the same solution at a target dose of 250±10 x 10⁶ viable cells per sample.

Trial Locations (1)

192019

St.-Petersburg Bekhterev Reserach Psychoneurological Institute, Saint Petersburg

All Listed Sponsors
lead

St. Petersburg Bekhterev Research Psychoneurological Institute

OTHER

NCT04710810 - UCB Stem Cells for Autism Spectrum Disorders | Biotech Hunter | Biotech Hunter